Cargando…
Targeting NK-1 Receptors to Prevent and Treat Pancreatic Cancer: A New Therapeutic Approach
Pancreatic cancer (PC) is the fourth leading cause of cancer related-deaths in both men and women, and the 1- and 5-year relative survival rates are 25% and 6%, respectively. It is known that smoking, alcoholism and psychological stress are risk factors that can promote PC and increase PC progressio...
Autores principales: | Muñoz, Miguel, Coveñas, Rafael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4586765/ https://www.ncbi.nlm.nih.gov/pubmed/26154566 http://dx.doi.org/10.3390/cancers7030832 |
Ejemplares similares
-
Neurokinin-1 Receptor Antagonists as Antitumor Drugs in Gastrointestinal Cancer: A New Approach
por: Muñoz, Miguel, et al.
Publicado: (2016) -
The NK-1 Receptor Antagonist L-732,138 Induces Apoptosis and Counteracts Substance P-Related Mitogenesis in Human Melanoma Cell Lines
por: Muñoz, Miguel, et al.
Publicado: (2010) -
Involvement of the Substance P/Neurokinin-1 Receptor System in Cancer
por: Coveñas, Rafael, et al.
Publicado: (2022) -
The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer?
por: Muñoz, Miguel, et al.
Publicado: (2020) -
The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia
por: Muñoz, Miguel, et al.
Publicado: (2020)